If you or someone you care for is taking Tysabri, you may be wondering what ongoing monitoring for PML actually involves. The medical community has developed structured surveillance protocols based on years of clinical evidence. This page summarizes the key components of that monitoring and the evidence supporting them.
Tysabri (natalizumab) is a biologic therapy approved for relapsing forms of multiple sclerosis (MS) and moderately to severely active Crohn's disease (CD) in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus (JCV). The following narrative synthesizes medical evidence and risk considerations for patients and attorneys evaluating potential legal claims related to Tysabri-associated PML. Clinical Presentation and Diagnosis of PML PML is an infection of the brain's white matter that typically leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Symptoms may include progressive weakness on one side of the body, vision changes, confusion, and difficulty with speech or coordination. Diagnosis relies on brain MRI showing characteristic lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. Early recognition is critical because the infection can progress rapidly. In clinical trials, PML occurred in three patients who received Tysabri: two among 1869 MS patients treated for a median of 120 weeks (both also received interferon beta-1a), and one after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri is a monoclonal antibody that binds to alpha-4 integrin, blocking immune cell migration into the central nervous system. This mechanism reduces inflammation in MS but also impairs normal immune surveillance against JCV. The JC virus is a common, usually harmless virus that remains latent in the kidneys and lymphoid tissue. In immunocompromised individuals, particularly those with reduced T-cell function, JCV can reactivate and infect oligodendrocytes in the brain, leading to PML. Tysabri's effect on immune trafficking creates a state of relative immunosuppression in the brain, allowing JCV to proliferate unchecked. This mechanistic pathway is supported by the observation that PML risk increases with longer treatment duration and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three established risk factors for PML in Tysabri-treated patients are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information includes a boxed warning stating that Tysabri increases PML risk and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also instructs healthcare professionals to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called TOUCH, designed to ensure patients are informed of PML risks and monitored regularly (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether prescribers adequately communicated the magnitude of risk, especially for patients with multiple risk factors, and whether monitoring protocols were followed appropriately.
PML can develop after varying durations of Tysabri therapy. In clinical trials, one case occurred after eight doses in a Crohn's disease patient, while two MS cases occurred after a median of 120 weeks (approximately 2.3 years) of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The risk appears to increase with cumulative exposure, particularly beyond two years. For patients who develop PML, the timeline from symptom onset to diagnosis is critical because early detection and immune reconstitution (e.g., plasma exchange to remove Tysabri) may improve outcomes. Delays in diagnosis due to failure to recognize early symptoms or to perform appropriate testing can lead to more extensive brain damage and poorer prognosis.
Patients who develop PML after Tysabri treatment may have legal claims based on inadequate warning, failure to monitor, or failure to promptly diagnose. Key considerations include: whether the prescribing physician discussed the specific risk factors (anti-JCV antibody status, treatment duration, prior immunosuppressant use) with the patient; whether the patient was enrolled in the TOUCH program and received appropriate monitoring; and whether any signs or symptoms of PML were overlooked or misattributed to MS relapse. The boxed warning explicitly states that risk factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). If a patient was not tested for anti-JCV antibodies before or during therapy, or if treatment continued beyond two years without reassessment of risk-benefit, these factors may support a claim. Additionally, the label notes that Tysabri should not be used in combination with immunosuppressants or TNF-alpha inhibitors in Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962); concurrent use of such agents may increase PML risk and could be relevant in litigation.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its mechanism of blocking immune cell migration into the central nervous system (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Legal claims may involve inadequate warnings, failure to monitor for PML, or delayed diagnosis. Key factors include whether the physician discussed risk factors, whether the patient was in the TOUCH program, and whether symptoms were overlooked (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.